11 results on '"Wilson, Reece"'
Search Results
2. Survey of Pharmacists' Knowledge of Connecticut's Medical Cannabis Program
- Author
-
Kumar Mukherjee, Lisa M. Holle, and Sara Wilson Reece
- Subjects
Pharmacology ,Health Knowledge, Attitudes, Practice ,Self-Assessment ,medicine.medical_specialty ,State law ,education ,Medical Marijuana ,Pharmacists ,Connecticut ,Cross-Sectional Studies ,Complementary and alternative medicine ,Surveys and Questionnaires ,Family medicine ,Medical cannabis ,medicine ,Humans ,Pharmacology (medical) ,Education, Pharmacy, Continuing ,Psychology ,Original Research ,Legalization - Abstract
Introduction: Over the last few years, a growth in research and interest in medical cannabis (most often referred to as medical marijuana) use have occurred nationally. Medical cannabis has become a treatment option for disease conditions, such as epilepsy, wasting syndrome associated with AIDs, and post-traumatic stress disorder, when traditional medication is ineffective. Objectives: The objectives were to identify knowledge deficits of the medical cannabis program (MCP) in Connecticut among Connecticut pharmacists and the impact of MCP on Connecticut pharmacy practice and concerns Connecticut pharmacists have regarding medical cannabis use. Methods: A cross-sectional survey through an online platform, Google forms, was administered for 2 months (October 15, 2017–December 15, 2017). An e-mail containing the link to the survey was e-mailed to all pharmacists whose e-mail addresses were available from the State of Connecticut's Commission of Pharmacy database (n = 6182). Of those with available e-mail addresses, only 5653 pharmacists received the e-mail; the others were rejected upon receipt of our e-mail. Our survey consists of 16 items related to pharmacist demo- graphic information, knowledge assessment, impact on pharmacists' practice, and concerns stemming from medical cannabis. Results: Only 51 (15.2%) respondents believed that Connecticut MCP would impact their practice. Only 39 (11.6%) respondents selected the two correct requirements for patient registration and correctly identified the wrong choices. Only 81 (24.2%) respondents identified the correct approved dose (maximum allowable monthly amount of 2.5 ounces) of medical cannabis. Sixty-eight (20.2%) respondents correctly identified all three approved conditions and all other incorrect conditions. Sixty-five (19.40%) respondents correctly identified all roles of dispensary pharmacists. Majority of respondents, 243 (72.5%), expressed their concern about federal laws regarding cannabis. A total of 98 (29.3%) respondents thought that they were knowledgeable enough about the side effects of medical cannabis to provide appropriate counseling to patients. Conclusion: Overall, the results of our survey found that Connecticut licensed pharmacists had lack of complete and accurate knowledge regarding the state's MCP. As more states legalize medical cannabis, it will be imperative that education of pharmacists and other health care professionals about the MCP and the clinical use of cannabis occur.
- Published
- 2021
3. Meckel’s Diverticulum Causing Small Bowel Intussusception in Third Trimester Pregnancy, a Case Report
- Author
-
Wilson, Reece Eric and Wilson, Reece Eric
- Published
- 2020
4. Retrospective Review of Maternal and Fetal Outcomes in Patients With Gestational Diabetes Mellitus in an Indigent Prenatal Clinic
- Author
-
Harish S. Parihar, Mark Martinez, and Sara Wilson Reece
- Subjects
medicine.medical_specialty ,Departments ,endocrine system diseases ,Endocrinology, Diabetes and Metabolism ,Population ,03 medical and health sciences ,0302 clinical medicine ,Diabetes mellitus ,Internal Medicine ,medicine ,030212 general & internal medicine ,Medical nutrition therapy ,education ,Glycemic ,education.field_of_study ,Pregnancy ,030219 obstetrics & reproductive medicine ,Obstetrics ,business.industry ,medicine.disease ,Metformin ,Gestational diabetes ,Care Innovations ,Postprandial ,business ,medicine.drug - Abstract
Gestational diabetes mellitus (GDM) is diabetes that is diagnosed during the second or third trimester of pregnancy and is not clearly overt diabetes (1). Diagnosis is defined by severity of carbohydrate intolerance. The upper end of the GDM diagnostic glucose range is the same as would be indicative of diabetes outside of pregnancy, whereas the lower end of the GDM range is only slightly above normal and asymptomatic but still associated with increased risk of fetal morbidity (1,2). Diabetes during pregnancy is diagnosed by either a one-step approach involving a 75-g oral glucose tolerance test (OGTT) or a two-step approach starting with a 50-g (nonfasting) screen followed by a 100-g OGTT for those who initially screen positive (1). Glycemic goals for patients with a GDM diagnosis are as follows: preprandial ≤95 mg/dL and either 1-hour postprandial ≤140 mg/dL or 2-hour postprandial ≤120 mg/dL. Hyperglycemia throughout pregnancy carries increased risk for adverse fetal and maternal outcomes (3–8). Treatment of diabetes during pregnancy is aimed at decreasing the risk of perinatal outcomes such as macrosomia, birth trauma, neonatal metabolic abnormalities, and cesarean section (4,9–12). Lifestyle modification is first-line treatment and includes medical nutrition therapy (MNT), exercise, and glucose monitoring (13). Pharmacological therapy generally consists of insulin, glyburide, or metformin, and agents may be used adjunctly to MNT depending on presence and severity of hyperglycemia (13). Insulin is the preferred pharmacological treatment for management of diabetes in pregnancy if lifestyle modification is insufficient in achieving euglycemia (13). The setting of this review is the diabetes clinic located within the Hall County Health Department (HCHD) prenatal clinic in Gainesville, Ga. The population of Gainesville is ∼187,000 and includes a large percentage of Latino immigrants (14). The proportion of Latinos in the diabetes clinic has grown …
- Published
- 2018
5. Insulin Pump Class: Back to the Basics of Pump Therapy
- Author
-
Cheryl Lynn Hamby Williams and Sara Wilson Reece
- Subjects
Insulin pump ,medicine.medical_specialty ,Departments ,business.industry ,Endocrinology, Diabetes and Metabolism ,Insulin ,medicine.medical_treatment ,Insulin sensitivity ,medicine.disease ,On board ,Regimen ,Bolus (medicine) ,Endocrinology ,Diabetes mellitus ,Internal medicine ,Internal Medicine ,medicine ,business ,Glycemic - Abstract
In the early 1960s, Dr. Arnold Kadish developed the first insulin pump, which was the size of a Marine backpack.1 Over the years, insulin pumps have become much more refined and have decreased in bulk to the size and weight of a small pager. Insulin pump therapy, also known as continuous subcutaneous insulin infusion, is no longer seen as experimental and controversial, but rather is viewed as an acceptable alternative to multiple daily injection (MDI) therapy in the management of insulin-dependent diabetes2 (Table 1).3 The insulin pump is an electromechanical device that mimics the body's natural insulin secretion from pancreatic β-cells by subcutaneously delivering rapid-acting insulin both at preset continuous basal rates and in extra bolus doses at mealtimes on demand.4 Insulin pumps allow for up to 24 different hourly basal rates in a 24-hour period. For bolus doses, pump users input their current blood glucose level and the number of carbohydrates they will consume, and the pump customizes their dose based on insulin currently on board (i.e., the remaining active insulin from the previous dose), their individualized insulin-to-carbohydrate ratio, and their individualized insulin sensitivity factor (i.e., their expected drop in blood glucose from 1 unit of insulin).1,5 Thus, insulin pumps are able to deliver insulin in a more physiological manner than other injection-based insulin regimens.5 In the late 1970s, results of the first human trials of insulin pump therapy were published. This was followed by numerous additional studies comparing insulin pump therapy to traditional MDI regimens with regard to long-term glycemic control and minimization of hypoglycemia.6–11 Then, in 1993, the Diabetes Control and Complications Trial12 confirmed the importance of intensive glycemic control using either insulin pump therapy or an MDI regimen along with frequent self-monitoring of …
- Published
- 2014
6. Making Time and Creating Space for Undergraduate Research
- Author
-
Myers, Joy, primary, Sawyer, Amanda G., primary, Dredger, Katie, primary, Barnes, Susan, primary, and Wilson, Reece, primary
- Published
- 2018
- Full Text
- View/download PDF
7. Gestational Diabetes Clinic in the Public Health Setting
- Author
-
Sara Wilson Reece
- Subjects
Glycosuria ,medicine.medical_specialty ,Pregnancy ,endocrine system diseases ,business.industry ,Obstetrics ,Endocrinology, Diabetes and Metabolism ,nutritional and metabolic diseases ,Type 2 diabetes ,medicine.disease ,female genital diseases and pregnancy complications ,Preeclampsia ,Gestational diabetes ,Endocrinology ,Insulin resistance ,Diabetes mellitus ,Internal medicine ,Internal Medicine ,medicine ,medicine.symptom ,business ,Neonatal Hyperglycemia - Abstract
Gestational diabetes mellitus (GDM), or “carbohydrate intolerance of variable severity with onset or first recognition during pregnancy,” results from insulin resistance and relative insulin deficiency, usually in the second trimester.1 This condition affects between 4 and 9% of all pregnancies.2 With GDM, there are increased fetal complications of macrosomia, shoulder dystocia, and neonatal hyperglycemia, as well as maternal risks of preeclampsia and polyhydramnois.3,4 Also, it has been shown that 33% of GDM patients require Cesarean section compared to 20% of pregnant patients without GDM.5 Women who are of Hispanic or Asian descent are at the highest risk of developing GDM.6 According to the American Diabetes Association (ADA),7 assessment for undiagnosed type 2 diabetes should be completed at the first prenatal visit. Patients who are high risk (those with severe obesity, a history of GDM, a diagnosis of polycystic ovarian syndrome, a strong family history of type 2 diabetes, or glycosuria) should be screened using standard diagnostic testing. Diagnosis is based on the following results: A1C ≥ 6.5%, fasting plasma glucose level ≥ 126 mg/dl, 2-hour plasma glucose level ≥ 200 mg/dl during an oral glucose tolerance test (OGTT), or classic symptoms of hyperglycemia with a random blood glucose level ≥ 200 mg/dl.7 All remaining pregnant women who are not known to have diabetes should have testing for GDM at 24–28 weeks of gestation using a 75-g, 2-hour OGTT. Patients are diagnosed with GDM if they have any of the following plasma glucose values: fasting ≥ 92 mg/dl, 1-hour ≥ 180 mg/dl, or 2-hour ≥ 153 mg/dl.7 Upon diagnosis of GDM, medical nutrition therapy, self-monitoring of blood glucose (SMBG), and fetal monitoring are initiated. A study by Landon et al.8 found that treatment of mild GDM resulted in a lower …
- Published
- 2011
8. Metformin in gestational diabetes mellitus
- Author
-
Harish S. Parihar, Sara Wilson Reece, and Christina LoBello
- Subjects
medicine.medical_specialty ,Pregnancy ,Departments ,endocrine system diseases ,Obstetrics ,business.industry ,Endocrinology, Diabetes and Metabolism ,Neonatal hypoglycemia ,nutritional and metabolic diseases ,Overweight ,medicine.disease ,Metformin ,Pharmacy and Therapeutics ,Gestational diabetes ,Shoulder dystocia ,Obstetrics and gynaecology ,Diabetes mellitus ,Internal Medicine ,medicine ,medicine.symptom ,business ,medicine.drug - Abstract
As currently diagnosed, gestational diabetes mellitus (GDM) affects 5–9% of all pregnancies in the United States and is growing in prevalence.1 It is defined as carbohydrate intolerance of variable severity that is first recognized during pregnancy. Although GDM has been recognized for decades, the potential significance of the condition, as well as criteria for screening and diagnosis, remain debatable.1 Historically, GDM has been treated with lifestyle modifications and insulin, and oral antihyperglycemic agents have been used infrequently because of concerns regarding neonatal hypoglycemia and teratogenicity. Most recent studies suggest that oral hypoglycemic agents, specifically metformin, are safe to use during pregnancy (Table 1).2–13 Risk for developing GDM has been noted in women who are overweight before pregnancy, have had GDM in a previous pregnancy, or have a family history of diabetes. Poorer outcomes have been seen in both pregnant women and their developing fetuses, including induction of labor and caesarean delivery in women and death, shoulder dystocia, bone fracture, and nerve palsy in fetuses.1 Moreover, recent studies show that diagnosis and management of this disorder will have beneficial effects on both maternal and neonatal outcomes.14,15 According to the American College of Obstetrics and Gynecology, comprehensive screening techniques have been implemented by > 90% of practices in the United States.16 Reasons for the implementation of screening programs were developed from the evidence obtained in the Hyperglycemia and Adverse Pregnancy Outcomes study.17 This large, prospective, observational study found possible adverse effects associated with even mild maternal hyperglycemia. It included a cohort of women with glucose levels at the upper end of the normal range, as well as women with mild GDM. The investigators found a linear correlation between higher levels of maternal glucose and adverse outcomes, including increased birth weight, …
- Published
- 2015
9. Examining Perspectives of Faculty and Students Engaging in Undergraduate Research.
- Author
-
Myers, Joy, Sawyer, Amanda G., Dredger, Katie, Barnes, Susan K., and Wilson, Reece
- Subjects
STUDENT engagement ,ACADEMIC motivation ,UNDERGRADUATE programs ,TEACHER education ,UNDERGRADUATES ,ATTITUDE (Psychology) - Abstract
This case study analyzes one research collaboration between faculty and undergraduates at a teaching-intensive university within a teacher education program working to expand opportunities for undergraduates to engage in meaningful research. It examines how researchers perceive the opportunities and obstacles associated with such research. Data included written and oral reflections and field notes of the project participants, members of the research group. The study offers insight into how one group of teacher educators embedded undergraduate research into an existing research project and the opportunities and obstacles that the faculty and students encountered. Faculty involved in this study perceived opportunities for technology support, honest conversations and thoughtful collaboration, authentic interpretation, debunking misconceptions, and for taking time. Undergraduates perceived opportunities to experience and understand the research process, to make new relationships, and to learn from others. Faculty perceived obstacles included the paperwork, the lack of basic methodological training, and the lack of academic writing experience on the part of the undergraduates. Obstacles that were perceived by the undergraduates included logistical issues such as transportation and lack of background information about their role in the project prior to the project start, project pacing, and their confidence in their own contributions to the group. Opportunities outweighed obstacles in this research endeavor. This collaboration became an exercise in reflective practice and continual learning and has implications for the undergraduates involved to see themselves as researchers as they continue their professional careers as teachers. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
10. Metformin in Gestational Diabetes Mellitus.
- Author
-
Wilson Reece, Sara, Parihar, Harish S., and LoBello, Christina
- Published
- 2014
11. TRAIN LIKE A WORLD CUP RACER.
- Author
-
Wilson, Reece
- Published
- 2019
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.